for Previously Treated ERBB2(HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases:Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.JAMA Oncol.2023 Feb 1;9(2):197-205.
《2022 ASCO Educational Book》发表的一篇报道“Systemic Therapy for HER2-Positive Metastatic Breast Cancer:Moving Into a New Era”指出,当前HER2阳性转移性乳腺癌(MBC)的治疗目标是根据疾病和患者的特征量身定制治疗强度,以提高治愈率,同时将过度治疗风险降到最低,这为制定HER2阳性MBC的治疗策略提示了重要方向。
2022 ASCO Educational Book发表的一篇报道“Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era”指出,当前HER2阳性转移性乳腺癌(MBC)的治疗目标是根据疾病和患者的特征量身定制治疗强度,以提高治愈率,同时...
[3]Swain SM,Baselga J,Miles D,et al.Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab,trastuzumab,and docetaxel:results from the randomized phase III...
[18] Xu B, Ma F, Ouyang Q, et al. Abstract PD3-08: A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab[J]. 2018. ...
9、Hurvitz,Sara A et al.“Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer:updated results from DESTINY-Breast03,a randomised,open-label,phase 3 trial.”Lancet(London,England)vol.401,10371(2023):105-117.doi:10.1016/S0140-6736(22)02420-5...
1. Gion M, Trapani D, Cortés A, et al. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-11. 2. Romond EH, et al. Seven year follow-up assessment of cardiac functionin NSABPB-31. a randomized trial co...
[8]Sara A. Hurvitz, et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. 2023 ESMO 377O....
[10] Xu, Binghe, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Oncology 22.3 (2021): 351-360. ...
3.Sartore-Bianchi, A., et al., Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol, 2016. 17(6): p. 738-...